2024
Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.
Blondin N, Haberli N. Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis. Journal Of Clinical Oncology 2024, 42: 2029-2029. DOI: 10.1200/jco.2024.42.16_suppl.2029.Peer-Reviewed Original ResearchNon-small cell lung cancerDiagnosis of LMNational Comprehensive Cancer NetworkLeptomeningeal metastasesTumor cell assayPositive CTCsCerebrospinal fluidData cutoffOverall survivalNeurological symptomsAssessment of circulating tumor DNASensitivity of tumor cell detectionCTC assayManagement of leptomeningeal metastasisTime of data cutoffDiagnosis of leptomeningeal metastasisAssociated with longer survivalMedian overall survivalOmmaya reservoir placementEnumeration of circulating tumor cellsNegative cytology resultsCell lung cancerEffective treatment optionProgressive neurological symptomsInitiation of treatment
2017
CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA
Jameyfield E, Blondin N. CMET-07. VISMODEGIB TREATMENT OF INTRACRANIAL INVASION OF BASAL CELL CARCINOMA. Neuro-Oncology 2017, 19: vi40-vi40. PMCID: PMC5691966, DOI: 10.1093/neuonc/nox168.156.Peer-Reviewed Original ResearchMetastatic basal cell carcinomaBasal cell carcinomaCell carcinomaIntracranial invasionInitial treatmentNeurological symptomsScalp woundsVismodegib treatmentScalp basal cell carcinomasMonths of treatmentBest treatment optionYear old manLeft frontal lobeFurther medical attentionFocal cerebritisAge 78BCC patientsIncomplete resectionComplete responseScalp lesionsIntracranial complicationsTreatment optionsVasogenic edemaMohs surgeryPrevalent cancer